MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Search

TG Therapeutics Inc

Chiusa

SettoreSettore sanitario

29.24 -1.98

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

28.9

Massimo

29.27

Metriche Chiave

By Trading Economics

Entrata

363M

391M

Vendite

21M

162M

P/E

Media del settore

11.102

88.032

Margine di Profitto

241.727

Dipendenti

374

EBITDA

-4.9M

33M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+46.86% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-499M

4.8B

Apertura precedente

31.22

Chiusura precedente

29.24

Notizie sul Sentiment di mercato

By Acuity

50%

50%

142 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

TG Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 gen 2026, 22:45 UTC

I principali Market Mover

GH Research Shares Up, Plans to Provide Update on New Drug Application

4 gen 2026, 23:50 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Rises Amid Geopolitical Risks After Maduro's Ouster -- Market Talk

4 gen 2026, 23:50 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Nikkei May Decline After Removal of Venezuela's Maduro -- Market Talk

4 gen 2026, 23:41 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Forex and Fixed Income Roundup: Market Talk

4 gen 2026, 23:40 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Markets Mostly Calm as Venezuelan Raid Weighed -- Market Talk

4 gen 2026, 23:35 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Declines on Oversupply Worries After Maduro's Ouster -- Market Talk

4 gen 2026, 23:19 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Energy Roundup: Market Talk

4 gen 2026, 23:19 UTC

Discorsi di Mercato
Principali Notizie su Eventi

ONGC Could Receive $500M in Unpaid Dividends From U.S. Takeover of Venezuelan Oil -- Market Talk

4 gen 2026, 23:17 UTC

Principali Notizie su Eventi

Spot Gold Rises 0.8% to $4,365.24/oz

4 gen 2026, 23:16 UTC

Principali Notizie su Eventi

Spot Gold Rises After U.S.' Removal of Venezuela's Maduro

4 gen 2026, 23:14 UTC

Principali Notizie su Eventi

Front-Month WTI Crude Oil Futures Fall 0.6%; Front-Month Brent Crude Oil Futures Drop 0.5%

4 gen 2026, 23:13 UTC

Principali Notizie su Eventi

Front-Month Crude Oil Futures Fall After Ouster of Venezuela's Maduro

4 gen 2026, 23:12 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Reliance Industries' Could Benefit from U.S. Takeover of Venezuelan Oil -- Market Talk

4 gen 2026, 22:37 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Can Gain From Flight to Quality, Central Bank Demand After Maduro Ouster -- Market Talk

4 gen 2026, 21:00 UTC

Utili

An On-Time Jobs Report. Plus, Albertsons, Constellation, Jefferies, and More Stocks to Watch this Week. -- Barrons.com

4 gen 2026, 20:49 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Energy Roundup: Market Talk

4 gen 2026, 20:49 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Jitters About Potential for U.S. Actions Elsewhere Could Grow -- Market Talk

3 gen 2026, 18:59 UTC

Principali Notizie su Eventi

Update: Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3 gen 2026, 17:42 UTC

Principali Notizie su Eventi

The Oil Sector's Biggest Winners and Losers From Venezuela Regime Change -- Barrons.com

3 gen 2026, 17:40 UTC

Principali Notizie su Eventi

Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3 gen 2026, 16:10 UTC

Principali Notizie su Eventi

What Maduro's Capture Means for Chevron Stock -- Barrons.com

3 gen 2026, 15:53 UTC

Principali Notizie su Eventi

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3 gen 2026, 15:03 UTC

Principali Notizie su Eventi

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3 gen 2026, 14:10 UTC

Principali Notizie su Eventi

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3 gen 2026, 12:16 UTC

Principali Notizie su Eventi

U.S. Captures Maduro, Trump Says -- Barrons.com

3 gen 2026, 09:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

3 gen 2026, 09:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

3 gen 2026, 00:43 UTC

Acquisizioni, Fusioni, Takeovers

Research Reports -- Barrons.com

2 gen 2026, 22:13 UTC

Discorsi di Mercato
Utili

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

TG Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

46.86% in crescita

Previsioni per 12 mesi

Media 43 USD  46.86%

Alto 60 USD

Basso 13 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TG Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

3

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 34.86Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

142 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat